Vertex Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VRTX and other ETFs, options, and stocks.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
CEOReshma Kewalramani
CEOReshma Kewalramani
Employees5,400
Employees5,400
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded1989
Founded1989
Employees5,400
Employees5,400
VRTX Key Statistics
Market cap103.11B
Market cap103.11B
Price-Earnings ratio-205.08
Price-Earnings ratio-205.08
Dividend yield—
Dividend yield—
Average volume2.63M
Average volume2.63M
High today$407.06
High today$407.06
Low today$399.45
Low today$399.45
Open price$404.54
Open price$404.54
Volume591.02K
Volume591.02K
52 Week high$519.88
52 Week high$519.88
52 Week low$377.85
52 Week low$377.85
VRTX News
The Motley Fool 2d
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the DipEvery investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice that's less simple to apply. What exactly qualifies as "low"? One...
Simply Wall St 4d
High Growth Tech Stocks To Watch In December 2024The United States market has recently experienced a notable upswing, climbing by 2.8% over the past week and achieving a 24% increase over the past year, with e...
The Motley Fool 4d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the DipVertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical tri...
Analyst ratings
61%
of 36 ratingsBuy
61.1%
Hold
30.6%
Sell
8.3%